$15.020
+0.152 (+1.01%)At close
MNMD News
MNMD Events
Mind Medicine Announces Q3 Earnings Per Share of 78 Cents, Exceeding Consensus Estimate of 50 Cents
"2025 continues to be a year of strong execution, and our recent $258.9 million financing further strengthens our position as we prepare for a transformational 2026," said Rob Barrow, Chief Executive Officer of MindMed. "Enrollment across all three pivotal MM120 ODT trials remains on track. Given faster than expected enrollment in Emerge, our first Phase 3 study in MDD, we have accelerated guidance for topline data readout which is now expected in mid-2026. We plan to initiate Ascend, our second Phase 3 study in MDD, in mid-2026 and remain focused on advancing toward FDA submissions in both generalized anxiety disorder (GAD) and major depressive disorder (MDD). We are also excited to advance our pipeline with the start of a Phase 2a study of MM402 in ASD. With multiple anticipated Phase 3 topline data readouts ahead, 2026 is set to be the most significant year in our history to date, as our team works to bring new treatment options to both providers and patients."
Mind Medicine Prices 18.375M Share Spot Secondary Offering at $12.25
Jefferies, Leerink and Evercore ISI acted as joint book running managers for the offering.
Mind Medicine Reveals Common Shares and Warrants Offering, Amount Not Disclosed
Mind Medicine announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general corporate purposes. MindMed may also use a portion of the net proceeds to invest in or acquire additional businesses or compounds that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any future acquisitions as of this date. Jefferies, Leerink Partners, and Evercore ISI are acting as the joint bookrunning managers for the offering.
Mind Medicine Reveals Results from Phase 2b Study of MM120
Mind Medicine announced that JAMA has published full results from the Company's Phase 2b study of MM120 in 198 adults with moderate-to-severe GAD. This is the first randomized, placebo-controlled trial to evaluate a single treatment across four dose levels as a monotherapy and did not include any form of study-related psychotherapeutic intervention. The study met its primary and key secondary endpoints, with MM120 demonstrating a dose-response relationship and significant symptom improvement versus placebo on the Hamilton Anxiety Rating Scale, a validated clinical tool used to assess the severity of anxiety. The 100 microgram dose of MM120, now being evaluated in three pivotal Phase 3 trials, showed the optimal level of clinical activity in the study. At Week 4, it achieved a 7.6-point greater reduction in HAM-A scores compared to placebo with a 65% clinical response rate and 48% clinical remission rate sustained to Week 12. MM120 was generally well-tolerated in this study, with most adverse events rated as mild-to-moderate, transient, occurring on the dosing day, and being consistent with the expected acute effects of the trial drug. Based on these Phase 2b study results and the significant unmet medical need in the treatment of GAD, the U.S. Food & Drug Administration has provided Breakthrough Therapy Designation to MM120 for GAD. Pre-specified secondary outcomes in the study included changes from baseline in HAM-A; clinician-rated disease severity measured by Clinical Global Impression-Severity scale and changes from baseline in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale, in addition to measures of functional disability and quality of life. CGI-S scores on average improved from 4.8 to 2.2 in the 100 microgram dose group, representing a two-category shift from 'markedly ill' to 'borderline ill' at Week 12, compared with 4.9 to 3.5 in the placebo group. Clinical activity was rapid, observed as early as study day 2, and durable, with further improvements observed in mean HAM-A or CGI-S scores between Weeks 4 and 12. MADRS score improvements in the 100 microgram arm of the study were clinically and statistically significant compared to the placebo group, with a difference of 5.7 points at Week 4 and a difference of 6.4 points at Week 12. The dose-response results support the selection of MM120 100 microgram for the Company's ongoing Phase 3 development program for MM120 Orally Disintegrating Tablet. MindMed is currently enrolling participants in its Voyage and Panorama Phase 3 studies to assess the efficacy, durability, and safety of MM120 ODT in the treatment of GAD, and in its Emerge study to assess MM120 ODT for the treatment of major depressive disorder. Topline data for Voyage is expected in the first half of 2026 and for Panorama and Emerge in the second half of 2026.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.